Emideltide (DSIP)
Also known as: Delta sleep-inducing peptide, DSIP, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Overview
Emideltide, commonly called delta sleep-inducing peptide (DSIP), is a nine–amino acid peptide originally described in the context of sleep physiology research. It is best known for reported effects on sleep architecture—particularly delta (slow-wave) activity and spindle patterns—across a mixed body of animal experiments and limited human observations summarized in reference databases. Emideltide is not an FDA-approved drug, and modern clinical development is sparse compared with mainstream neuropeptides. Interest persists because DSIP shows up repeatedly in older neuroscience and stress-physiology literature, and because it is sometimes discussed in contemporary peptide-compounding debates as a 'wellness' peptide despite the lack of a current, high-quality clinical evidence base. From a practical standpoint, the key uncertainty is mechanism: DSIP has been associated with changes in neuroendocrine and neurotransmitter signaling in preclinical models, but there is no consensus target receptor the way there is for many hormone analogs. Any discussion of dosing, delivery route, or therapeutic claims should be framed as research-context only, with a strong emphasis on evidence limitations.
Mechanism of Action
Mechanism of action is not well established. Reference summaries describe DSIP as a neuromodulatory peptide associated with increased delta and spindle EEG patterns and broader effects on neurotransmitter and hormonal systems, but without a single validated receptor target in humans.
Potential Benefits
- Older preclinical and small pilot work describes effects on slow-wave (delta) EEG and sleep spindles.
- Reported in mid-20th-century literature as a stress-resilience modulator in animal models.
- Cited in some neuroendocrine studies for effects on cortisol and thyroid-axis signaling.
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Consult published research literature for study-specific protocols.
Routes of Administration
Research / non-approved Not established
No FDA-approved route of administration.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Reconstitution
| Storage | Refer to supplier documentation |
|---|
Need exact syringe measurements?
Amino Acid Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Side Effects & Safety
- Human safety data are limited.
- Quality, purity, and dosing uncertainties apply to any non-approved peptide.
- Not recommended for use outside controlled research.
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / nursing
No human safety data; avoid use.
Pediatric population
No pediatric safety data.
Drug Interactions
- CNS depressants: Theoretical additive effect with sedatives, hypnotics, alcohol given purported sleep-related activity.
Pharmacokinetics
| Half-Life | Not well characterized in modern clinical pharmacokinetic literature. |
|---|---|
| Storage | Reference-stage peptide; storage conditions not standardized. |
Synergistic Compounds
The following compounds have been studied alongside Emideltide (DSIP) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.
MetaVia's DA-1726 posts -9.1% Phase 1 weight loss and FibroScan signals at EASL Congress 2026
MetaVia's DA-1726 Phase 1 readout at EASL 2026 showed -9.1% body weight at Day 54 and directional liver-fat improvement in the 48 mg cohort, no plateau.
Alabama medical board bans research-grade peptide prescribing, closes consent-form workaround
Alabama's medical board on May 26 prohibited physicians from prescribing, compounding, or administering any non-FDA-approved peptide, with no consent-form exception.